Wells Fargo analyst Yanan Zhu downgraded Gracell (GRCL) to Equal Weight from Overweight with a $10 price target after Gracell entered into a definitive agreement to be acquired by AstraZeneca (AZN) for $10.00 per ADS in cash at closing, plus a non-tradable contingent value right for up to $1.50 per ADS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRCL:
- Gracell downgraded to Neutral from Buy at BTIG
- Gracell downgraded to Neutral from Buy at H.C. Wainwright
- M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B
- M & A News: AstraZeneca (NASDAQ:AZN) to Acquire Gracell for $1.2B
- Gracell jumps 61% to $9.97 after AstraZeneca buyout agreement
